Home Stock

Stock Research: Fulcrum Therapeutics

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Fulcrum Therapeutics

NMQ:FULC US3596161097
28
  • Value
    76
  • Growth
    26
  • Safety
    Safety
    49
  • Combined
    45
  • Sentiment
    15
  • 360° View
    360° View
    28
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small molecules for genetically defined rare diseases. It operates in the biopharmaceutical industry, focusing on therapies for conditions like sickle cell disease and inherited aplastic anemias (Diamond-Blackfan anemia, Shwachman-Diamond syndrome, and Fanconi anemia). In the last fiscal year, the company had 45 employees, a market cap of $425 million, $0 profits, and $80 million in revenue.

more

ANALYSIS: With an Obermatt 360° View of 23 (better than 23% compared with alternatives), overall professional sentiment and financial characteristics for the stock Fulcrum Therapeutics are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Fulcrum Therapeutics. Only the consolidated Value Rank has an attractive rank of 74, which means that the share price of Fulcrum Therapeutics is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 74% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 28, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 48, meaning the company has a riskier financing structure than 52% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 91% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 9. ...read more

more
Strongest Rank Analyst Opinions
Weakest Rank Pro Holdings
Country USA
Industry Pharmaceuticals
Size Small
Website fulcrumtx.com
Index
NASDAQ
Fulcrum Therapeutics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 8-Jun-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
76 63 29 39
Growth
26 19 97 19
Safety
Safety
49 65 79 79
Sentiment
15 10 54 59
360° View
360° View
28 49 17 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
1 1 39 47
Opinions Change
4 50 72 50
Pro Holdings
n/a 25 54 73
Market Pulse
49 32 41 42
Sentiment
15 10 54 59
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
76 63 29 39
Growth
26 19 97 19
Safety Safety
49 65 79 79
Combined
45 54 82 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
48 54 3 11
Price vs. Earnings (P/E)
64 18 18 18
Price vs. Book (P/B)
73 73 62 54
Dividend Yield
1 1 1 1
Value
76 63 29 39
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
1 8 81 13
Profit Growth
39 89 60 37
Capital Growth
67 27 99 15
Stock Returns
4 17 61 83
Growth
26 19 97 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
73 100 100 73
Refinancing
44 92 83 81
Liquidity
25 1 6 6
Safety Safety
49 65 79 79

Similar Stocks

Discover high‑ranked alternatives to Fulcrum Therapeutics and broaden your portfolio horizons.

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Penske Automotive

NYQ:PAG
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

VSE

NSQ:VSEC
Country: USA
Industry: Aerospace & Defense
Size: Medium
Full Stock Analysis

Western Alliance Bank

NYQ:WAL
Country: USA
Industry: Regional Banks
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

The only strength is good value. All other factors (growth, safety, and sentiment) are below average. This stock is highly sensitive to a crisis and is not advisable. Avoid unless you have solid, independent reasons to believe a significant turnaround is imminent.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews